M Andreeff

Author PubWeight™ 234.98‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991 3.52
2 Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000 3.50
3 Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000 2.86
4 MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 2007 2.79
5 Flow cytometry in clinical cancer research. Cancer Res 1983 2.72
6 A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001 2.71
7 Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002 2.68
8 Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001 2.52
9 Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 2008 2.50
10 Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens. Am J Clin Pathol 1999 2.38
11 Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes. J Exp Med 1984 2.26
12 Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001 2.21
13 Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000 2.11
14 Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 1994 2.09
15 Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med 1993 2.09
16 High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood 1992 2.07
17 Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992 2.05
18 Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization. Science 1990 1.90
19 Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994 1.85
20 Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008 1.84
21 Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996 1.82
22 Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999 1.76
23 Influenza among hospitalized adults with leukemia. Clin Infect Dis 1997 1.68
24 Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. J Natl Cancer Inst 1997 1.63
25 The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol 2007 1.62
26 Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia 2002 1.62
27 Cytokine-regulated expression of survivin in myeloid leukemia. Blood 2001 1.56
28 Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood 1991 1.56
29 MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia 2008 1.53
30 The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. Cytotherapy 2008 1.52
31 Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 2000 1.52
32 Effects of extracellular matrix on the response of endothelial cells to radiation in vitro. Eur J Cancer 1992 1.51
33 The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 2008 1.48
34 Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia 2005 1.44
35 The PML gene encodes a phosphoprotein associated with the nuclear matrix. Blood 1995 1.44
36 Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia 2003 1.39
37 Apoptosis. Molecules and mechanisms. Adv Exp Med Biol 1999 1.30
38 MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia 2011 1.30
39 The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells. Leukemia 2005 1.30
40 Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene 1989 1.30
41 Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood 1980 1.29
42 Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991 1.27
43 Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 2004 1.24
44 Apoptosis effector mechanisms: a requiem performed in different keys. Apoptosis 2006 1.22
45 BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res 2000 1.22
46 Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood 1998 1.22
47 Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995 1.18
48 Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis 1995 1.17
49 Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. Clin Cancer Res 1996 1.17
50 Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL. Leukemia 2003 1.16
51 A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J Clin Oncol 1988 1.13
52 Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. Gene Ther 1995 1.13
53 Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999 1.11
54 Changes of cellular markers during differentiation of HL-60 promyelocytes to macrophages as induced by T lymphocyte conditioned medium. Leuk Res 1981 1.11
55 Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 1996 1.11
56 The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene 2011 1.11
57 Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 1997 1.10
58 Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997 1.09
59 Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. Leukemia 2009 1.09
60 The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res 1999 1.08
61 Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ 2007 1.08
62 Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood 1999 1.07
63 Characterization of hematologic malignancies by flow cytometry. Blood Cells 1980 1.04
64 Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology. Cytometry 1993 1.04
65 Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia 2011 1.03
66 hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther 2002 1.02
67 A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood 1996 1.02
68 [Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations]. Nuklearmedizin 2009 1.02
69 Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis. Leukemia 2009 1.01
70 Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia 2011 1.01
71 Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha. Cancer Res 1994 1.01
72 Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995 1.00
73 Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 1995 1.00
74 Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer 1995 1.00
75 Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol. Int J Cancer 1998 0.99
76 Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses. Hum Gene Ther 2004 0.99
77 E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 2000 0.98
78 Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Cancer Gene Ther 2009 0.97
79 Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 1993 0.97
80 Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 1998 0.97
81 Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts. Leukemia 2011 0.96
82 Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 1999 0.96
83 Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1. Cell Death Differ 2007 0.95
84 Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation. Oncogene 2006 0.95
85 Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemia. Am J Med 1998 0.95
86 Different sensitivity of chromatin to acid denaturation in quiescent and cycling cells as revealed by flow cytometry. J Histochem Cytochem 1979 0.94
87 PKC alpha mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation. Leukemia 2004 0.94
88 Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996 0.93
89 Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr Pharm Des 2005 0.93
90 Preparation and biodistribution of rhenium-188 labeled albumin microspheres B 20: a promising new agent for radiotherapy. Appl Radiat Isot 2000 0.92
91 Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/APO-1 by irradiation and ara-C treatment. Cell Death Differ 1998 0.92
92 Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia 1998 0.92
93 Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia. Br J Haematol 1998 0.92
94 Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol 1999 0.92
95 Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol 1999 0.92
96 Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia 2006 0.92
97 Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990 0.92
98 Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia and expression of apoptosis-regulating genes. Cytometry 2000 0.91
99 Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther 2001 0.91
100 Bcl2 phosphorylation and active PKC alpha are associated with poor survival in AML. Leukemia 2006 0.91
101 Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation. Leukemia 2005 0.91
102 Modulation of drug sensitivity by dipyridamole in multidrug resistant tumor cells in vitro. Cancer Res 1990 0.91
103 Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996 0.90
104 Induction of in vitro proliferation and maturation of human aneuploid myelogenous leukemic cells. J Exp Med 1982 0.90
105 Detection of dual TEL-ABL transcripts and a Tel-Abl protein containing phosphotyrosine in a chronic myeloid leukemia patient. Leukemia 2002 0.90
106 Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. Transplantation 1999 0.90
107 Activation of p21WAF1/Cip1 expression by a temperature-sensitive mutant of human p53 does not lead to apoptosis. Oncogene 1995 0.89
108 Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid. Cancer Res 1993 0.89
109 Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 1999 0.89
110 Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. Br J Haematol 1998 0.89
111 MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML. Leukemia 2011 0.89
112 Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer 2001 0.89
113 A knowledge-based system for the interpretation of flow cytometry data in leukemias and lymphomas. Cytometry 1994 0.89
114 Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center. Semin Oncol 1989 0.88
115 Expression of the macrophage growth factor, CSF-1 and its receptor c-fms by a Hodgkin's disease-derived cell line and its variants. Cancer Res 1990 0.87
116 CD30 ligand is expressed on resting normal and malignant human B lymphocytes. Br J Haematol 1996 0.87
117 Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia. Am J Clin Pathol 1999 0.87
118 Rescue from apoptosis in early (CD34-selected) versus late (non-CD34-selected) human hematopoietic cells by very late antigen 4- and vascular cell adhesion molecule (VCAM) 1-dependent adhesion to bone marrow stromal cells. Cell Growth Differ 1998 0.87
119 Bone marrow cell count per cubic millimeter bone marrow: a new parameter for quantitating therapy-induced cytoreduction in acute leukemia. Blood 1982 0.87
120 HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML. Leukemia 2012 0.87
121 Involvement of retinoic acid receptor-alpha-mediated signaling pathway in induction of CD38 cell-surface antigen. Blood 1997 0.87
122 Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice. Oncogene 2006 0.87
123 CD30 ligand in lymphoma patients with CD30+ tumors. J Clin Oncol 1997 0.87
124 The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. Blood 1996 0.86
125 Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 1997 0.86
126 Acanthamoeba meningoencephalitis after bone marrow transplantation. Bone Marrow Transplant 1994 0.86
127 Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Cancer Res 1998 0.86
128 Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia 2009 0.86
129 Adenovirus as a gene therapy vector for hematopoietic cells. Cancer Gene Ther 2000 0.86
130 Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents. Oncogene 1998 0.86
131 Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma. Cytokines Mol Ther 1996 0.85
132 Lymphoblastic neoplasia in a homosexual patient with Kaposi's sarcoma. Ann Intern Med 1983 0.85
133 Characterization of two newly established human cell lines from patients with large-cell anaplastic lung carcinoma. Cancer 1982 0.85
134 Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Clin Cancer Res 1999 0.84
135 Cell kinetics in acute leukemia: a critical reevaluation based on new data. Cancer 1982 0.84
136 Fluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia. Blood 1993 0.84
137 Prognostic value of DNA/RNA flow cytometry of B-cell non-Hodgkin's lymphoma: development of laboratory model and correlation with four taxonomic systems. Ann N Y Acad Sci 1986 0.84
138 Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor. Oncogene 2011 0.84
139 Discrimination of cycling and non-cycling lymphocytes by BUdR-suppressed acridine orange fluorescence in a flow cytometric system. Exp Cell Res 1978 0.84
140 PML/RARalpha, a fusion protein in acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells. Clin Cancer Res 1995 0.84
141 RNA content in human lymphocyte subpopulations. Proc Natl Acad Sci U S A 1978 0.84
142 Polysomy of chromosome 12 in 60 patients with non-Hodgkin's lymphoma assessed by fluorescence in situ hybridization: differences between follicular and diffuse large cell lymphoma. Genes Chromosomes Cancer 1994 0.83
143 Allogeneic T cell activation triggering by MHC class I antigens. J Immunol 1988 0.83
144 Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumor necrosis factor as ligand for the CD95 receptor. Blood 2001 0.83
145 Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML. Apoptosis 2014 0.83
146 Physiological hypoxia promotes lipid raft and PI3K-dependent activation of MAPK 42/44 in leukemia cells. Leukemia 2010 0.83
147 Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. Leuk Lymphoma 1999 0.83
148 All-trans retinoic acid converts E2F into a transcriptional suppressor and inhibits the growth of normal human bronchial epithelial cells through a retinoic acid receptor- dependent signaling pathway. J Clin Invest 1998 0.83
149 Recognition of central nervous system leukemia by flow cytometry. Cytometry 1984 0.82
150 Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia. Cancer Res 1992 0.82
151 Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity. Clin Cancer Res 1998 0.82
152 Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells. Leukemia 1999 0.82
153 Phase I study of taxol in refractory acute myelogenous leukemias using a weekly schedule. Acta Haematol 1998 0.82
154 Quantitative expression of proliferating cell nuclear antigen by western blot (PCNAWB) in peripheral blasts correlates with remission induction in patients with acute myelogenous leukemia. Leuk Lymphoma 1995 0.81
155 Expression of MDR1 by normal bone marrow cells and its implication for leukemic hematopoiesis. Leuk Lymphoma 1995 0.81
156 Functional expression of TRAIL by lymphoid and myeloid tumour cells. Br J Haematol 1999 0.81
157 Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol 2001 0.81
158 A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia 1995 0.81
159 Cellular ras oncogene expression and cell cycle measured by flow cytometry in hematopoietic cell lines. Blood 1986 0.81
160 Acute lymphoblastic leukemia in adults. Semin Oncol 1985 0.81
161 Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. Leukemia 1989 0.81
162 Detection of luxol-fast-blue positive cells in human promyelocytic leukemia cell line HL-60. Exp Hematol 1981 0.81
163 Progression of nodular poorly differentiated lymphocytic lymphoma to Burkitt's-like lymphoma. Blood 1984 0.81
164 Effect of very high-dose thymidine infusions on leukemia and lymphoma patients. Cancer Res 1984 0.80
165 Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin. Proc Natl Acad Sci U S A 1995 0.80
166 S phase determination in intact colonic crypts by histone H3 messenger RNA in situ hybridization and confocal microscopy. Cancer Epidemiol Biomarkers Prev 1997 0.80
167 Expression of CD95(FAS) by gene transfer does not sensitize K562 to Fas-killing. Hematol Cell Ther 1997 0.80
168 Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia. Blood 1998 0.80
169 Multiparameter flow cytometry. Part I: application in analysis of the cell cycle. Clin Bull 1981 0.80
170 [Beta-radiation exposure at the finger tips during the radionuclide synovectomy]. Nuklearmedizin 2003 0.79
171 Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis. Cancer 1995 0.79
172 Further characterization of cyclophosphamide resistance: expression of CD95 and of bcl-2 in a CML cell line. Leuk Res 1998 0.79
173 Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemic lymphocytes. Blood 1997 0.79
174 [Oncogens and cancer. Review and a new method for measuring the gene expression in relation to the cell cycle]. Dtsch Med Wochenschr 1985 0.79
175 Retracted Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression. Blood 1991 0.79
176 CD38 in hematopoietic malignancies. Chem Immunol 2000 0.79
177 DNA and RNA determination in 111 cases of childhood acute lymphoblastic leukaemia (ALL) by flow cytometry: correlation of FAB classification with DNA stemline and proliferation. Br J Haematol 1985 0.79
178 Low incidence of MDR1 expression in acute promyelocytic leukaemia. Br J Haematol 1995 0.79
179 Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia. Cytometry 1994 0.79
180 DNA and RNA flow cytometric study in multiple myeloma. Clinical correlations. Cancer 1991 0.78
181 Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia 1995 0.78
182 Cellular pharmacology of mitoxantrone in p-glycoprotein-positive and -negative human myeloid leukemic cell lines. Leukemia 1997 0.78
183 In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study. Blood 1995 0.78
184 Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia. Cancer Res 1984 0.78
185 Cell survival kinetics in peripheral blood and bone marrow during total body irradiation for marrow transplantation. Int J Radiat Oncol Biol Phys 1983 0.78
186 Synthetic triterpenoids have cytotoxicity in pediatric acute lymphoblastic leukemia cell lines but cytotoxicity is independent of induced ceramide increase in MOLT-4 cells. Leukemia 2007 0.78
187 Ratio of bcl-xshort to bcl-xlong is different in good- and poor-prognosis subsets of acute myeloid leukemia. Mol Med 1998 0.78
188 Bone marrow biopsy instead of 'marrow juice' for cell kinetic analysis. Comparison of bone marrow biopsy and aspiration material. Leuk Res 1982 0.78
189 Cell kinetics of leukemia. Semin Hematol 1986 0.78
190 [Ventilation-perfusion-lungscintigraphy using PET and 68Ga-labeled radiopharmaceuticals]. Nuklearmedizin 2010 0.78
191 High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Cytokines Mol Ther 1995 0.77
192 Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood 1996 0.77
193 Cell kinetic analysis of intact rat colonic crypts by confocal microscopy and immunofluorescence. Gastroenterology 1996 0.77
194 Activation of retinoid receptors RAR alpha and RXR alpha induces differentiation and apoptosis, respectively, in HL-60 cells. Cell Growth Differ 1996 0.77
195 Acute lymphoblastic leukemia following preleukemic syndromes in adults. Leukemia 1996 0.77
196 Unbalanced expression of Fas and CD40 in mantle cell lymphoma. Br J Haematol 1998 0.77
197 Biosynthesis of ferritin subunits from different cell lines of HL-60 human promyelocytic leukaemia cells and the release of acidic isoferritin-inhibitory activity against normal granulocyte-macrophage progenitor cells. Br J Haematol 1983 0.77
198 Minimal residual disease (MRD) in remission t(8;21) AML and in vivo differentiation detected by FISH and CD34+ cell sorting. Leukemia 2001 0.77
199 Analysis of chimerism following allogeneic bone marrow transplantation by fluorescent-in-situ hybridization. Leuk Lymphoma 1997 0.77
200 2-Chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome. Leukemia 1997 0.77
201 Combination treatment of acute myeloblastic leukemia with rhGM-CSF and standard induction chemotherapy. Cancer Invest 1993 0.77
202 Bcl-2 is expressed in human natural killer cells and is regulated by interleukin-2. Nat Immun 1998 0.77
203 Minimal residual disease in acute myelogenous leukaemia and myelodysplastic syndromes: a follow-up of patients in clinical remission. Br J Haematol 1997 0.76
204 Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells. J Immunol 1998 0.76
205 Detection of central nervous system relapse in acute leukemia by multiparameter flow cytometry of DNA, RNA, and CALLA. Ann N Y Acad Sci 1986 0.76
206 Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma. Br J Cancer 2010 0.76
207 Non-T, non-B acute lymphoblastic leukemia (L3) with t(8;22) and two 14q+ chromosomes. Cancer Genet Cytogenet 1983 0.76
208 Sodium azide enhancement of interleukin-2 production. Blood 1983 0.76
209 Expression of bcr-abl mRNA in individual chronic myelogenous leukaemia cells as determined by in situ amplification. Br J Haematol 2001 0.76
210 Purging of contaminating breast cancer cells from hematopoietic stem cell grafts by adenoviral GAL-TEK gene therapy and magnetic antibody cell separation. Clin Cancer Res 1999 0.76
211 Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Clin Cancer Res 1998 0.76
212 Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leuk Lymphoma 1993 0.76
213 Cellular uptake and localization of liposomal-methylphosphonate oligodeoxynucleotides. J Mol Med (Berl) 1996 0.76
214 Transduction of MDR1 into human and mouse haemopoietic progenitor cells: use of rhodamine (Rh123) to determine transduction frequency and in vivo selection. Br J Haematol 1995 0.76
215 Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide. Int J Cancer 1997 0.76
216 Surface immunoglobulin light chain expression in pre-B cell leukemias. Ann N Y Acad Sci 1986 0.76
217 Heterogeneity of cell lineages in L3 leukemias. Blood 1980 0.75
218 Proliferation of hematopoietic cells is accompanied by suppressed expression of heat shock protein 70. Biochem Biophys Res Commun 1992 0.75
219 Analysis of p53 gene deletions in patients with non-Hodgkin's lymphoma by dual-colour fluorescence in-situ hybridization. Br J Haematol 1997 0.75
220 Large-scale preparation of highly purified, frozen/thawed CD34+, HLA-DR- hematopoietic progenitor cells by sequential immunoadsorption (CEPRATE SC) and fluorescence-activated cell sorting: implications for gene transduction and/or transplantation. Bone Marrow Transplant 1994 0.75
221 Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia. Leuk Lymphoma 1994 0.75
222 Etoposide as an in vitro purging agent for the treatment of acute leukemias and lymphomas in conjunction with autologous bone marrow transplantation. Exp Hematol 1986 0.75
223 Phase II study of interleukin-6 in patients with smoldering relapse of acute myelogenous leukemia. Leukemia 1995 0.75
224 Prognostic value of DNA/RNA flow cytometry in myeloblastic and lymphoblastic leukemia in adults: RNA content and S-phase predict remission duration and survival in multi-variate analysis. Ann N Y Acad Sci 1986 0.75
225 Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts. Med Pediatr Oncol Suppl 1992 0.75
226 High incidence of monosomy 18 in lymphoid malignancies that have bone marrow and peripheral blood involvement. Cancer Genet Cytogenet 1994 0.75
227 Cytokinetics of a human neuroblastoma cell line following treatment with dianhydrogalactitol. Cancer Invest 1985 0.75
228 T-cell-depleted autologous marrow fails to prevent acute graft-versus-host disease after allogeneic marrow transplantation for lymphoblastic lymphoma. Transplant Proc 1992 0.75
229 DNA and RNA analysis by flow cytometry of the leukemia in AKR mice. Leuk Res 1985 0.75
230 A pilot study of high-dose interleukin-3 treatment of relapsed follicular small cleaved-cell lymphoma: hematologic, immunologic, and clinical results. Blood 1996 0.75
231 Sensitivity of combined DNA/immunophenotype flow cytometry for the detection of low levels of aneuploid lymphoblastic leukemia cells in bone marrow. Cytometry 1997 0.75
232 Prognostic significance of terminal deoxynucleotidyl transferase activity in acute nonlymphoblastic leukemia. J Clin Oncol 1986 0.75
233 [Summary: Therapy of chronic myelogenous leukemia--prognosis]. Internist (Berl) 1980 0.75
234 CD30-ligand and CD40-ligand expression in lymph nodes involved with Hodgkin's disease. Ann Oncol 1997 0.75
235 Enhancement of apoptosis in irradiated glioblastoma cells by pentoxifylline. Oncol Rep 2011 0.75
236 Surface marker analysis and flow cytometric studies of acute nonlymphocytic leukemias in children and young adults. Clin Immunol Immunopathol 1979 0.75
237 Multiparameter flow cytometry. Part II. application in hematology. Clin Bull 1981 0.75
238 Common acute lymphoblastic leukemia characterized by four different DNA stemlines with heterogeneity in RNA content, antigen expression and sensitivity to chemotherapy. Leuk Res 1986 0.75
239 Clonal stability and heterogeneity of hybridomas: analysis by multiparameter flow cytometry. Hybridoma 1985 0.75
240 [Determination of radioactivity by smartphones]. Nuklearmedizin 2013 0.75
241 Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia. Exp Hematol 1992 0.75
242 Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs. Leukemia 1994 0.75
243 A semi-automated system for concentration of rhenium-188 for radiopharmaceutical applications. Appl Radiat Isot 2008 0.75
244 Use of prognostic factors in deciding therapy for adult acute lymphoblastic leukemia: new approaches at Memorial Sloan-Kettering Cancer Center (MSKCC). Bone Marrow Transplant 1989 0.75
245 Chromosome X numerical abnormalities in patients with non-Hodgkin's lymphoma. A study of 59 patients using fluorescence in situ hybridization. Cancer Genet Cytogenet 1995 0.75
246 Semi-automated PCR method for quantitating MDR1 expression. Biotechniques 1996 0.75
247 CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia. Leuk Lymphoma 1998 0.75
248 Characterization of cultured human tumor cell lines by flow cytometry DNA stemline. Anal Quant Cytol 1981 0.75
249 Acute non-lymphoblastic leukemia after treatment of nodular lymphoma with human leukocyte interferon. Ann Intern Med 1983 0.75
250 [Comparison of the therapeutic efficacity of 2 induction protocols in acute myeloid leukemia using exact quantification of bone marrow cellularity]. Onkologie 1983 0.75
251 Chromosome 17 numerical abnormalities in 55 patients with non-Hodgkin's lymphoma: a fluorescence in situ hybridization study. Leukemia 1995 0.75
252 Acute myeloblastic leukemia following non-Hodgkin lymphoma in an adolescent. A report of a case with preleukemic syndrome, and review of the literature. Med Pediatr Oncol 1981 0.75
253 Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance. Leukemia 1995 0.75
254 Current status of treatment of acute leukemia in adults: an overview of the Memorial experience and review of literature. Crit Rev Oncol Hematol 1986 0.75
255 Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study. Clin Cancer Res 1998 0.75
256 Quantitation of chemotherapy-induced cytoreduction in acute leukemia. Haematol Blood Transfus 1981 0.75
257 Childhood CML in blastic stage: an analysis of cell markers and cell kinetics. Am J Hematol 1980 0.75
258 The coexistence of acute myeloblastic leukemia and diffuse histiocytic lymphoma in the same patient as demonstrated by multiparameter analysis. Blood 1979 0.75
259 [Autoregulatory growth inhibition in experimental tumors]. Verh Dtsch Ges Inn Med 1975 0.75
260 [Interpretation of differencies in the DNA-values of exfoliated cells in gynecologic smears (author's transl)]. Verh Dtsch Ges Pathol 1973 0.75
261 Idarubicin in acute leukemia: results of US trials. Bone Marrow Transplant 1989 0.75
262 Implications of 'cell kill' for the treatment of acute myelogenous leukemia: can the cure rate be increased? Acta Haematol 1989 0.75
263 Cytokine expression of T cells in chronic myeloid leukemia. Chin Med J (Engl) 2000 0.75
264 Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis. J Clin Apher 2001 0.75
265 [The value of impulse cytophotometry in the examination of ascitic fluid, contents of cysts and secretions from the cul-de-sac]. Geburtshilfe Frauenheilkd 1973 0.75
266 Molecular analysis of an AIDS-associated Burkitt's lymphoma: near-identity with endemic cases. Curr Top Microbiol Immunol 1988 0.75
267 [3D segmenting method for volume quantification of ECT (emission-computed tomography) data]. Biomed Tech (Berl) 1998 0.75
268 GM-CSF in combination with cytotoxic chemotherapy in AML patients. Bone Marrow Transplant 1990 0.75
269 Genetic therapy of human neoplastic disease. J Hematother 1993 0.75
270 The phosphorylation of retinoblastoma gene product in human myeloid leukemia cells during the cell cycle. Biochem Biophys Res Commun 1992 0.75
271 [Pro and con: Aggressive or conventional treatment of chronic myelogenous leukemia. Arguments in favor of aggressive treatment]. Internist (Berl) 1980 0.75
272 Distinct antigen expression related to DNA ploidy in a case of biphenotypic leukemia. Leukemia 1989 0.75
273 Serum LDH values in childhood acute leukemias and non-Hodgkin's lymphoma. Med Pediatr Oncol 1984 0.75
274 Retinoids and cancer therapy. J Natl Cancer Inst 1992 0.75
275 [Effect of various new cytostatic agents on DNA reduplication and proliferation kinetics in the Ehrlich-Lettre ascites tumor model]. Verh Dtsch Ges Inn Med 1974 0.75
276 Minimal residual disease in hematologic malignancies. Rev Invest Clin 1994 0.75
277 Growth-factor stimulation reveals two mechanisms of retinoblastoma gene inactivation in human myelogenous leukemia cells. Leuk Lymphoma 1995 0.75
278 A pilot study of the biologic and therapeutic effects of granulocyte colony-stimulating factor (filgrastim) in patients with acute myelogenous leukemia. Leukemia 1995 0.75
279 Cell differentiation effects of 2'-fluoro-1-beta-D-arabinofuranosyl pyrimidines in HL-60 cells. Leuk Res 1987 0.75
280 Inhibition of telomerase activity correlates with a decrease in the RNA component of telomerase during differentiation. Int J Oncol 1997 0.75
281 Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991 0.75
282 Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: absence of prognostic correlations. Leuk Lymphoma 1997 0.75
283 Importance of long-term follow-up in evaluating treatment regimens for adults with acute lymphoblastic leukemia. Haematol Blood Transfus 1990 0.75
284 Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl. Leuk Lymphoma 1996 0.75
285 [Diastolic murmur caused by a phaeochromocytoma (author's transl)]. Dtsch Med Wochenschr 1975 0.75
286 [Effect of corrective procedures on volume quantification of SPECT data]. Biomed Tech (Berl) 1998 0.75
287 [Heart involvement in hemochromatosis]. Verh Dtsch Ges Inn Med 1971 0.75
288 Proliferation of human hematopoietic progenitors in long-term bone marrow cultures in gas-permeable plastic bags is enhanced by colony-stimulating factors. Exp Hematol 1992 0.75
289 A diagnostic workstation for neoplastic bone marrow diseases: evaluation on 526 cases. Medinfo 1995 0.75
290 Flow cytometry. Clinical and research applications in hematologic malignancies. Hematol Oncol Clin North Am 1994 0.75
291 Decreased expression of the deleted in colorectal carcinoma gene in non-Hodgkin's lymphoma. Blood 1995 0.75
292 Flow cytometric analysis of cytokinetics of L3-acute lymphoblastic leukemia/lymphoma. Leuk Res 1992 0.75
293 A study of multidrug resistance and cell kinetics in a child with near-haploid acute lymphoblastic leukemia. Leuk Res 1990 0.75
294 Prognostic factors in acute lymphoblastic leukemia in adults: the Memorial Hospital experience. Haematol Blood Transfus 1987 0.75